You are here

Study Evaluating Prevenar in the Prevention of Invasive Pneumococcal Disease (IPD) in the Paediatric Population in Spain.

Last updated on May 11, 2018

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Bilbao, , 48903 Spain
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Invasive Pneumococcal Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0-5
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- All children from 0 up to 5 years attending to the hospital's emergency department
will be evaluated for IPD.

- Diagnosis of IPD will be based on positive pneumococcal isolation in any sterile
location, such us blood or spinal fluid.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- All children from 0 up to 5 years attending to the hospital's emergency department
will be evaluated for IPD.

- Diagnosis of IPD will be based on positive pneumococcal isolation in any sterile
location, such us blood or spinal fluid.

NCT00227188
Pfizer
Completed
Study Evaluating Prevenar in the Prevention of Invasive Pneumococcal Disease (IPD) in the Paediatric Population in Spain.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
NCT03248882
All Genders
18+
Years
Multiple Sites
Pneumococcal Infections
NCT03512288
All Genders
0+
Years
Multiple Sites
Study Evaluating Prevenar in the Prevention of Invasive Pneumococcal Disease (IPD) in the Paediatric Population in Spain.
Effectiveness of Prevnar in the Prevention on IPD in the Paediatric Population in Spain
The aim of this study is to evaluate the postlicensure effectiveness of Prevnar in the prevention of IPD in the Spanish paediatric population (children younger than 5 years)
Not Provided
Observational
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:
Samples without DNA
Non-Probability Sample
All public and private hospitals with a pediatric department belonging to one of the two autonomous communities.
Invasive Pneumococcal Disease
Drug: Pneumococcal 7-valent conjugate vaccine Prevnar
Other Name: PREVNAR
1
Children from 0-5 years of age evaluated for IPD
Intervention: Drug: Pneumococcal 7-valent conjugate vaccine Prevnar
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
408
December 2005
December 2005   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • All children from 0 up to 5 years attending to the hospital's emergency department will be evaluated for IPD.
  • Diagnosis of IPD will be based on positive pneumococcal isolation in any sterile location, such us blood or spinal fluid.
Sexes Eligible for Study: All
up to 5 Years   (Child)
No
Contact information is only displayed when the study is recruiting subjects
Spain
 
 
NCT00227188
0887-101317
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
November 2012

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now